<DOC>
	<DOCNO>NCT01009879</DOCNO>
	<brief_summary>The purpose study determine effect TNF ( tumor necrosis factor ; mediator inflammation ) B cell patient rheumatoid arthritis . TNF B cell important rheumatoid arthritis appear involve cause rheumatoid arthritis .</brief_summary>
	<brief_title>Human Tumor Necrosis Factor Alpha ( TNFa ) -Induced Pre-B Cell Bone Marrow Emigrants</brief_title>
	<detailed_description>Primary Objective : The primary objective study identify early B cell bone marrow emigrants peripheral blood adult rheumatoid arthritis ( RA ) receive etanercept . Hypotheses : We believe peripheral blood RA patient contain early B cell bone marrow emigrant . We believe early B cell bone marrow emigrant induce TNFα . Primary Endpoint : The primary endpoint study quantification CD34+/CD19+ early B cell bone marrow emigrants peripheral blood subject . Study Design : Open-label , One Arm , Phase IV study 12 RA patient active disease receive etanercept .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Rheumatoid arthritis ( RA ) patient eligible study meet ACR criterion diagnosis RA ( Arnett et al . 1988 . The American Rheumatism Association 1987 revise criterion classification rheumatoid arthritis . Arthritis &amp; Rheumatism 31:315 . ) active disease ( ≥ 6 tender and/or swollen joint ) . Subjects must ≥ 18 year age . Subjects must rheumatoid factor ( RF ) positive ( RF titer great upper limit normal ) and/or antiCCP antibody positive ( antiCCP titer great upper limit normal ) . Subjects must negative TB skin test entry study negative screen chest xray PPD test inconclusive ( borderline , reactive nondiagnostic ) prior BCG inoculated subject . Female subject child bear potential ( exclude surgically sterile least 5 year postmenopausal ) must negative pregnancy test ( serum βHCG ) . Sexually active subject childbearing potential must agree use medically acceptable form contraception screen throughout study . Subjects designee must ability selfinject ENBREL caregiver home administer subcutaneous injection . Subjects must willing remain ENBREL ( 50 mg SQ qweek ) least 12 week take antirheumatic agent ( DMARDS and/or corticosteroid ) besides NSAIDs previous 4 week . The subject must able willing give write informed consent comply requirement study protocol must authorize release use protect health information . Before studyspecific procedure , appropriate write informed consent must obtain . RA patient exclude history congestive heart failure , recurrent active infection , positive PPD , history neurologic disease , Felty 's syndrome , hematologic malignancy liver disease . RA patient exclude WBC count &lt; 4.0 , Hct &lt; 30 liver profile abnormality ( &gt; 2x normal value AST , ALT , TBili and/or APhos ) . RA patient exclude previously treat antiTNFα therapy ( ENBREL , infliximab adalimumab ) , IL1ra , abatacept B T cell deplete therapy include rituximab alemtuzumab . Subjects previously receive DMARD therapy include methotrexate , leflunomide , sulfasalazine , hydroxychloroquine , gold , penicillamine , cyclosporine A , cyclophosphamide must take one medication within past 30 day prior institute ENBREL . General : Subject currently enrol another investigational device drug trial ( ) , subject receive investigational agent ( ) within 28 day baseline visit . Subjects know hypersensitivity Enbrel component know antibody etanercept . Prior concurrent cyclophosphamide therapy . Concurrent sulfasalazine therapy . Known HIVpositive , mycobacterial disease , active severe infection , untreated Lyme disease , severe comorbidities , history TB TB exposure , chronic hepatitis B hepatitis C , SLE , history multiple sclerosis , transverse myelitis , optic neuritis epilepsy , history recent alcohol substance abuse ( &lt; 1 year ) , pregnant lactating female and/or use live vaccine 90 day prior , study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>B lymphocyte</keyword>
</DOC>